Rab7依赖性STING降解受损在慢性乙型肝炎合并MASLD中抑制HBV复制但加速疾病进展
本研究探讨巨噬细胞STING在慢性乙型肝炎(CHB)合并代谢功能障碍相关脂肪性肝病(MASLD)中的作用。小鼠模型显示合并症降低HBV复制但加速肝炎症和纤维化,与巨噬细胞STING异常上调相关;HBV与脂毒性协同破坏Rab7功能,损害STING降解。恢复Rab7可促进STING降解并减轻病理,提示靶向Rab7降解STING是潜在治疗策略。
要点
- CHB合并MASLD时巨噬细胞Rab7功能受损导致STING异常累积。
- STING累积一方面增强抗病毒活性,另一方面促进炎症和肝损伤。
- 恢复Rab7促进STING降解可减轻肝脏病理,是潜在治疗靶点。
核心结论
- 在CHB-MASLD合并症中,Rab7功能受损导致巨噬细胞STING异常累积,抑制HBV复制但 paradoxically 加速肝病进展。
- 靶向Rab7降解过度STING代表一种新的治疗策略。
研究设计与样本
- 使用人类和小鼠肝组织评估STING表达水平。
- 采用髓系特异性STING敲除和肝细胞特异性STING敲入小鼠探索STING在合并症中的作用。
- 体外使用THP-1和HepG2.2.15/HepG2-NTCP共培养细胞,以棕榈酸(PA)刺激12小时进行机制研究。
- 使用肝类器官进行验证。
主要发现
- 小鼠CHB-MASLD合并症降低HBV复制但加速肝脏炎症和纤维化,与巨噬细胞STING异常上调相关。
- HBV与脂毒性协同破坏巨噬细胞Rab7表达和功能,通过自噬-溶酶体和内体-溶酶体途径损害STING降解。
- 胞质STING增强抗病毒活性(TBK1-IRF3-IFNβ)并促进炎症(NF-κB/NLRP3)。
- 细胞外囊泡将STING转运至肝细胞,触发内质网应激(PERK-CHOP),进一步激活NLRP3并加剧损伤。
- 恢复Rab7促进STING降解,减轻病理。
临床怎么用
- 在CHB合并MASLD患者中,需关注STING通路介导的炎症和肝损伤加速风险。
- 靶向Rab7促进STING降解可能成为改善CHB-MASLD合并症肝病进展的新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic hepatitis B (CHB), yet its impact on liver-related outcomes remains controversial. Although the stimulator of interferon genes (STING) pathway is pivotal in innate immunity, its involvement in CHB-MASLD comorbidity is undefined. OBJECTIVE: We aimed to elucidate the role and mechanism of macrophage STING in CHB-MASLD comorbidity. DESIGN: Human and mouse liver tissues were used to assess STING expression levels. Myeloid-specific STING knockout and hepatocyte-specific STING knock-in mice were used to explore the effects of STING in comorbidity. Tohoku Hospital Pediatrics (THP)-1 and HepG2.2.15/HepG2-NTCP co-cultured cells were stimulated with palmitic acid (PA) for 12 hours in vitro for mechanism research. Markers for STING, autophagy and endoplasmic reticulum stress (ERS) were assessed using western blot analysis, immunohistochemistry and immunofluorescence assays. The liver organoids were used for validation. RESULTS: CHB-MASLD comorbidity in mice decreased HBV replication but accelerated liver inflammation and fibrosis, linked to aberrant STING upregulation in macrophages. HBV synergised with lipotoxicity to disrupt Rab7 expression and function in macrophages, impairing STING degradation via autophagic-lysosomal and endosomal-lysosomal pathways. Pathological STING accumulation had dual effects: cytosolic STING enhanced antiviral activity (TANK-binding kinase 1-interferon regulatory factor 3-interferon beta) and promoted inflammation (nuclear factor kappa-B/NOD-like receptor family pyrin domain-containing 3 (NLRP3)). Extracellular vesicles transported STING to hepatocytes, triggering ERS (PKR-like endoplasmic reticulum kinase (PERK)-C/EBP homologous protein (CHOP)), further activating NLRP3 and exacerbating injury. Therapeutically, restoring Rab7 facilitated STING degradation, attenuating pathology. CONCLUSIONS: In CHB-MASLD comorbidity, impaired Rab7 function leads to aberrant STING accumulation in macrophages, suppressing HBV replication but paradoxically accelerating liver disease progression. Targeting Rab7 to degrade excessive STING represents a novel therapeutic strategy.
引用
- Wu W, Gao Q, Hai S, et al. Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD. Gut. 2026. PMID: 41775516. doi:10.1136/gutjnl-2026-338065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。